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Abstract Adhesion of platelets to the exposed extracellular
matrix proteins at sites of vascular injury is partly regulated
by the local £uid shear stress. Because the Leu33Pro (PlA)
polymorphism of integrin L3 confers only a modest increase in
adhesion under static conditions, we used CHO and 293 cells
expressing the Leu33 or Pro33 isoform of L3 in £ow chamber
experiments to test whether shear forces would alter the PlA
adhesive phenotype. We found that shear force augmented the
Pro33-mediated enhanced adhesion to ¢brinogen. This Pro33-
dependent enhancement was aspirin-sensitive and was also ob-
served on immobilized von Willebrand factor and cryoprecipi-
tate, but not ¢bronectin. Thus, shear stress enhances the adhe-
sive phenotype of the Pro33 cells to multiple physiologic
substrates.
, 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Ischemic myocardial and cerebral injury occurs when a
platelet thrombus occludes a vessel at the site of a ruptured
or eroded atherosclerotic plaque [1]. Platelets initiate hemo-
stasis by adhering to extracellular matrix (ECM) proteins in-
cluding von Willebrand factor (vWF), collagen, laminin and
¢bronectin in the subendothelium [2]. Firm platelet adhesion
to the subendothelium ¢rst requires a pronounced decelera-
tion via the interaction of the platelet glycoprotein (GP) Ib^
IX complex with vWF immobilized to ECM. Stable adhesion
is mediated through platelet integrins KIIbL3 (GPIIb^IIIa)
binding to immobilized ¢brin/¢brinogen and vWF, K2L1 bind-
ing to collagen, and K5L1 binding to ¢bronectin [3]. Subse-
quent thrombus formation depends upon platelet aggregation
and the crosslinking of platelets via the interaction of KIIbL3
with ¢brinogen and vWF.
Blood £ow through the vasculature imposes mechanical
shear stress on the vessel wall. Shear stress regulates vascular
endothelial cell cytoskeletal reorganization, activation of in-
tracellular signaling pathways, gene expression and protein
synthesis [4,5]. Endothelial integrin receptors act as biosensors
for the mechanotransduction of shear stress into biochemical
signals [6]. In addition, attachment of circulating platelets
(and leukocytes) to the vessel wall depends on the balance
between the shearing forces and the adhesive forces generated
by the interactions between cell surface receptors and their
ligands. As in the case of endothelial cells, blood £ow and
the associated shear stress have been shown to modulate
platelet function and signaling. For example, under high
£ow conditions such as those encountered in arterioles (wall
shear rates s 1000 s31), an interaction between platelet GPIb
and immobilized vWF is required for initial tethering, whereas
at lower shear rates, stable adhesion proceeds without this
requirement [7]. Under pathological high stress conditions,
platelets aggregate in the absence of modulators like ristocetin
and botrocetin and involves tyrosine phosphorylation of K-
actinin [8]. Furthermore, under the e¡ect of high shear stress
vWF can substitute for ¢brinogen as the KIIbL3 ligand during
platelet aggregation [9,10].
The L3 subunit of KIIbL3 is polymorphic at residue 33
(Leu33Pro), and the Pro33 variant (often referred to as the
PlA2 antigen) has been shown to be a risk factor for myocar-
dial infarction in some, but not all studies (for review see
reference [11]). There have been con£icting ¢ndings in in vitro
studies assessing the functional consequences of the Leu33Pro
polymorphism, perhaps due to di¡erences among the assays
used, the design of the studies, and donor-to-donor variations
in normal platelet function [12]. However, it is not known
whether £uid shear stress will modify the impact of the Leu33-
Pro polymorphism on cell adhesion to ¢brinogen and other
KIIbL3 ligands. Since adhesive di¡erences in our previous static
assays [13] between the Leu33 and Pro33 cells to ¢brinogen
were modest, we wondered if part of the confusion in genetic
epidemiological and in vitro functional studies might be re-
lated to Leu33Pro functional di¡erences under shear. We now
report that compared to static adhesion assays, £uid shear
stress further ampli¢es the enhanced adhesive phenotype of
Pro33 cells in a ligand-dependent fashion. Thus, the throm-
botic potential associated with the polymorphism may be
underestimated when tested under static conditions.
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2. Methods
2.1. Reagents
Anti-KIIbL3 monoclonal antibody (mAb) P2 was from Immunotech
(Marseilles, France). Blocking mAb 10E5 against KIIbL3 was a gift
from Dr. Barry Coller (The Rockefeller University, New York, NY,
USA). Human ¢bronectin, KMEM media, 0.05% trypsin, and G418
(Geneticin) were obtained from Life Technology Inc. (Gaithersburg,
MD, USA). Human ¢brinogen was from Enzyme Research Labora-
tories Inc. (South Bend, IN, USA). vWF at 100% of normal plasma
concentration puri¢ed from normal human cryoprecipitate [14] was a
gift from Dr. Joel Moake (Baylor College of Medicine, Houston, TX,
USA). Normal human cryoprecipitate was from the Blood Bank at
Johns Hopkins Hospital. Biochemical analysis of the cryoprecipitate
was determined by using STA analyzer kit (Diagnostica Stago,
France), and showed 0.60 mg/ml ¢brinogen and vWF at 44% normal
plasma concentration.
2.2. Cell lines and £ow cytometry
Stable Chinese hamster ovary (CHO) cell lines overexpressing the
Leu33 and Pro33 isoforms of KIIbL3 (designated Leu33 CHO and
Pro33 CHO) and the ‘vector only’ control CHO cells (designated
LK) were generated by £ow cytometric sorting using mAbs speci¢c
for KIIbL3 as previously described. A second set of cell lines was also
generated in the 293 human embryonal kidney cell line and described
previously [13]. Cell surface expression of KIIbL3 was analyzed by £ow
cytometry using P2 mAb followed by an anti-mouse FITC-labeled
antibody using a Beckman Coulter £ow cytometer, within 24 h of
each experiment to assure equivalent expression between the Leu33
and Pro33 cell lines. Cells were not used if there was a greater than
10% di¡erence in the expression of Leu33 and Pro33 isoforms.
2.3. Cell adhesion under £ow conditions
Cells were grown to 70^80% con£uence and detached using 0.05%
trypsin. After neutralization, cells were suspended in Tyrode’s or
Hanks’ balanced salt solution for adhesion studies to ¢brinogen or
¢bronectin respectively, as described previously [13]. For adhesion
studies under shear, glass coverslips (No. 1, 24U50 mm; Dow Corn-
ing, Corning, NY, USA) were coated with 12.5 Wg/ml ¢brinogen,
¢bronectin, cryoprecipitate or 100% of normal vWF plasma concen-
tration and incubated for 3 h in a humidi¢ed chamber. The parallel-
plate £ow chamber was assembled with the cover slip and the adhe-
sion assays under £ow performed as we have previously described
[15]. Brie£y, the £ow chamber was mounted on an inverted-stage
microscope (Nikon eclipse TE300, Nikon, Melville, NY, USA)
equipped with a 20U phase objective and a high-speed digital camera
(Quantix Photometric, Photometric Ltd, Tuscon, AZ, USA) con-
nected to a computer. In most experiments, 5U105 cells were perfused
through the chamber for 5 min at a constant £ow rate that corre-
sponds to the wall shear rates of 25, 50, 100 or 125 s31. In some
experiments, cells were pretreated for 30 min with 10 Wg/ml of 10E5
mAb or 300 Wg/ml of aspirin (Sigma, St. Louis, MO, USA) prior to
perfusion. Four ¢xed ¢elds of observation were identi¢ed and the
number of cells adhering onto the substrate in each region was
counted using the Metamorph imaging software (Universal Imaging
Corp., Downingtown, PA, USA).
In some experiments cells were £uorescently labeled with BCECF
dye (Molecular probes, Oregon) and perfused over ¢brinogen (100 Wg/
ml) in the parallel-plate perfusion chamber at wall shear rates of 25,
50 or 100 s31 for 5 min, as described [16]. Epi£uorescence was used to
directly visualize cell adhesion throughout the perfusion period and
experiments were recorded in real time with an sVHS video cassette
recorder. At the end of the perfusion, videotape images were digitized
and quantitative information on cell adhesion was obtained by digital
image processing, as previously described [16].
2.4. Immuno£uorescence
Integrin KIIbL3 distribution on CHO cells was examined in the
presence and absence of ¢brinogen binding. Adherent cells on cover-
slips were ¢xed with 3.5% paraformaldehyde for 8 min and blocked
with PBS containing 10% FCS for 20 min at 22‡C. Cells were immu-
nostained for KIIbL3 using integrin complex speci¢c P2 (20 Wg/ml)
antibody for 1 h at 22‡C followed by FITC-labeled anti-mouse IgG
(1:50) for 1 h at 22‡C. The coverslips were washed twice and mounted
in perma£uor (Lipshaw immunon, Pittsburgh, PA, USA). Fluorescent
images were obtained and analyzed using Metamorph imaging system.
2.5. Statistics
Results were expressed as meanUS.E.M. of 8^24 observations from
di¡erent experiments, and then analyzed by Student’s ‘t’ test.
3. Results
3.1. Shear ampli¢es the enhanced adhesion of Pro33 cells
to ¢brinogen
To determine whether £uid shear stress would modify the
adhesive phenotype of cells based on the PlA genotype, we
examined the adhesion of Leu33 and Pro33 cells to ¢brinogen
in the presence of shear. Signi¢cantly more Pro33 CHO cells
adhered on 100 Wg/ml ¢brinogen than did the Leu33 cells over
a range of wall shear rates (P9 0.05; Fig. 1A). The number of
CHO cells adhering to ¢brinogen was inversely proportional
to the wall shear rate with negligible adhesion occurring at
s 250 s31 (not shown). Adhesion was inhibited by the 10E5
mAb, indicating KIIbL3 dependence (Fig. 1B). Surface expres-
sion of KIIbL3 was not detectably di¡erent between cell lines
and could not account for the observed di¡erences in cell
adhesion (Fig. 1C).
Since plasma ¢brinogen levels have been shown to modify
the enhanced Pro33-dependent platelet aggregation [17], we
tested if a lower concentration of immobilized ¢brinogen
would modify the adhesion of Leu33 or Pro33 CHO cells.
Fig. 2A shows that the Pro33 cells adhered to a signi¢cantly
greater extent (P6 0.001) on 12.5 Wg/ml ¢brinogen compared
to the Leu33 cells at all shear rates tested. Surface expression
of KIIbL3 between cell lines was not detectably di¡erent (Fig.
2B), and this adhesion was KIIbL3 mediated (not shown). The
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Fig. 1. Adhesion of Leu33 and Pro33 CHO cells on 100 Wg/ml ¢-
brinogen. A: Cells were perfused over 100 Wg/ml ¢brinogen in a
parallel-plate £ow chamber and the number of adherent cells quan-
ti¢ed from three independent experiments. Compared to Leu33 cells,
Pro33 cells show 4.5-fold increased adhesion at 25 s31, 1.7-fold in-
creased adhesion at 50 s31, and 2.6-fold increased adhesion at
100 s31. *P6 0.001 for Leu33 vs. Pro33. B: Cells were pretreated
with 10 Wg/ml 10E5 and perfused as in panel A at a wall shear rate
of 50 s31. C: Mean £uorescence intensity of P2 binding to the three
cell lines.
FEBS 27056 25-3-03 Cyaan Magenta Geel Zwart
K.V. Vijayan et al./FEBS Letters 540 (2003) 41^4642
distribution patterns of integrin KIIbL3 were similar in Leu33
and Pro33 cells regardless of whether they were adhered to
¢brinogen (Fig. 3). This suggests that the enhanced adhesion
of Pro33 cells under £ow was most likely not caused by in-
creased integrin clustering. The observation that more cells
adhered at 12.5 Wg/ml compared to 100 Wg/ml ¢brinogen is
consistent with a previous study [18] in which the binding of
an anti-¢brinogen antibody linearly increased up to about
10 Wg/ml ¢brinogen and then declined at higher ¢brinogen
concentrations, and also with our previous static adhesion
study [13].
Although the CHO cells were generated by cell sorting and
should not exhibit clonal variations, we examined the in£u-
ence of shear on adhesion to ¢brinogen in a second set of cell
lines generated in 293 cells. Table 1 summarizes the e¡ect of
shear on adhesion to ¢brinogen mediated by Leu33 or Pro33
KIIbL3 expressing CHO and 293 cells. Similar results were
obtained with the 293 cells except that the Pro33-dependent
adhesive di¡erences were greatest at 50 s31 for the 293 cells,
and at 25 s31 for the CHO cells, perhaps re£ecting cell type
speci¢cities. However, both cell types showed an enhanced
Pro33 adhesion under shear compared to static conditions.
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Fig. 2. Adhesion of Leu33 and Pro33 CHO cells on 12.5 Wg/ml ¢-
brinogen. A: Cells were perfused over 12.5 Wg/ml ¢brinogen and the
number of adherent cells quanti¢ed from two to three independent
experiments. Compared to Leu33 cells, Pro33 cells show 2.8-fold in-
creased adhesion at 25 s31, 1.8-fold increased adhesion at 50 s31,
and 1.5-fold increased adhesion at 125 s31. *P6 0.001, VP=0.05;
2P=0.007 for Leu33 vs. Pro33. B: Mean £uorescence intensity of
P2 binding to the three cell lines.
Fig. 3. Fluorescence microscopy of integrin KIIbL3 distribution in CHO cells. A: Cells grown on coverslips were stained with P2 antibody fol-
lowed by FITC-labeled anti-mouse IgG. B: Cells that adhered to 12.5 Wg/ml ¢brinogen under shear (25 s31Þ were stained for integrin KIIbL3.
LK (vector cells) did not adhere to ¢brinogen and are not shown.
Table 1
Adhesion (in fold units) of Pro33 cells relative to Leu33 cellsa
Shear rate CHO cells 293 cells
0 (static) 1.2 (P6 0.001) 1.2 (P=0.006)
25 s31 2.8 (P6 0.001) 1.4 (P=0.005)
50 s31 1.8 (P=0.05) 2.2 (P=0.008)
125 s31 1.5 (P=0.007) 1.5 (P=0.07)
aAdhesion to 12.5 Wg/ml ¢brinogen.
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3.2. Enhanced adhesion of Pro33 CHO cells to ¢brinogen
depends on the cyclooxygenase (COX) pathway
Previous studies have demonstrated that aspirin (acetylsali-
cylic acid, ASA) inhibition of platelet function varies with
Leu33Pro genotype, with Pro33-positive platelets showing
greater sensitivity to inhibition by ASA [19^23]. These studies
were all conducted under static conditions, so we studied the
e¡ect of aspirin on the enhanced adhesion of Pro33 CHO cells
to ¢brinogen. Aspirin selectively inhibited the adhesion of
Pro33 cells and not Leu33 cells at all concentrations of ¢brin-
ogen (Table 2A) and all shear stresses (Table 2B). Interest-
ingly, at high ¢brinogen concentration and low shear stress,
ASA (300 Wg/ml) consistently enhanced the adhesion of Leu33
cells. However, the adhesion of Leu33 cells remained unaf-
fected at a low dose ASA (100 Wg/ml) while the enhanced
adhesion of Pro33 cells was selectively blocked (not shown).
Thus, the outcome of aspirin on the e¡ect of the Leu33Pro
polymorphism on cell adhesion is dependent on the substrate
density and the shear force.
3.3. Pro33 CHO cells demonstrate greater adhesion to vWF
and cryoprecipitate, but not to ¢bronectin
Platelet KIIbL3 interacts with multiple physiologic substrates
in vivo. Compared to the Leu33 cells, we also found that the
Pro33 variant exhibited signi¢cantly more adhesion to vWF
(1.5-fold) (Fig. 4A), but there was no signi¢cant di¡erence in
adhesion on ¢bronectin (Fig. 4B). This data indicates that the
increased adhesion of the Pro33 variant of L3 is substrate-
speci¢c. Cryoprecipitate is composed of vWF and ¢brinogen,
and is used clinically in the management of bleeding in certain
de¢ciency states. We observed signi¢cantly greater adhesion
for Pro33 cells compared to Leu33 cells on normal human
cryoprecipitate (Fig. 5A). This adhesion was KIIbL3 dependent
since it was blocked by 10E5 antibody (Fig. 5B).
4. Discussion
Fluid shear force is an important determinant of vascular
Table 2a
Relationship of ¢brinogen (FGN) concentration and aspirin on CHO cell adhesion
FGN Ethanol ASA (300 Wg/ml)
LK Leu33 Pro33 LK Leu33 Pro33
12.5 Wg/ml 18.33U 5.16 42U 5.91 89U5.91, P6 0.001* 15.33U4.27 44.22U 5.91, P=0.7842 56.11U 6.74, P=0.06*
50 Wg/ml 0.06U .06 18.18U 1.64 41.68U 2.85, P6 0.001* 0.375U .25 24.25U .972, P=0.0052 25.43U 1.75, P=0.437*
100 Wg/ml 0.33U .18 19.53U 2.10 46.93U 2.27, P6 0.001* 0.6U .23 28.13U 1.54, P=0.00092 31.13U 2.04, P=0.078*
Numbers in table are number of cells per microscopic ¢eld at a shear rate of 25 s31. *P values for Leu33 vs. Pro33. 2P values for Leu33 etha-
nol vs. Leu33 aspirin.
 
Fig. 4. Adhesion of Leu33 and Pro33 CHO cells on vWF and ¢bro-
nectin. Cells were perfused over vWF or ¢bronectin in a parallel-
plate £ow chamber and the number of adherent cells quanti¢ed
from two to three experiments. A: On a vWF substrate, the in-
creased adhesion of Pro33 cells is most prominent at 25 s31.
*P=0.007, #P=0.105; 2P=0.59 for Leu33 vs. Pro33. B, Adhesion
of Leu33 and Pro33 cells to 12.5 Wg/ml ¢bronectin from three ex-
periments. #Ps 0.28. C: Mean £uorescence intensity of P2 binding
to the three CHO cell lines determined within 24 h of the adhesion
assay. Surface expression of KIIbL3 was not detectably di¡erent be-
tween the Leu33 and Pro33 cells.
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Fig. 5. Adhesion of Leu33 and Pro33 CHO cells to normal human
cryoprecipitate. A: Cells were perfused over 12.5 Wg/ml cryoprecipi-
tate in a parallel-plate £ow chamber and the number of adherent
cells quanti¢ed from two to three experiments. Compared to Leu33
cells, Pro33 cells show 2.5-fold increased adhesion at 25 s31, 2.4-
fold increased adhesion at 50 s31, and 1.7-fold increased adhesion
at 125 s31. *P=0.003, 2P=0.002; VP6 0.001 for Leu33 vs. Pro33.
B, The 10E5 mAb (10 Wg/ml) blocked adhesion of both cell lines at
a wall shear rate of 25 s31. C: Mean £uorescence intensity of P2
binding to the three CHO cell lines.
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and blood cell function and plays an essential role in arterial
thrombosis. In this study, we have evaluated the impact of
shear stress on the adhesion to ECM proteins of CHO and
293 cells expressing the Leu33 or Pro33 isoforms of integrin
KIIbL3. Using a parallel-plate perfusion chamber, we showed
that compared to the Leu33 cells, Pro33 cells exhibited en-
hanced adhesion to ¢brinogen and vWF. This enhanced
Pro33 adhesion was mediated through integrin KIIbL3, was
substrate speci¢c, and required signaling through the COX
pathway. In addition, our ¢ndings suggest that aspirin may
enhance adhesion in Pro33-negative cells under low shear/high
¢brinogen conditions. The enhanced adhesive phenotype of
Pro33 cells under shear may have particular relevance in ar-
terial thrombosis.
In previous studies we have shown that CHO and 293 cells
expressing the Pro33 variant of KIIbL3 demonstrated a small
(V20% greater) but very reproducible increased adhesion to
immobilized ¢brinogen under static conditions [13]. Consider-
ing this modest e¡ect under static conditions, we wondered
whether shear might abolish the Pro33-mediated enhanced
adhesion to immobilized ¢brinogen. However, our studies
showed a clear enhancement of Pro33-mediated cell adhesion
to immobilized ¢brinogen under shear conditions compared
to static conditions. The shear e¡ect on Pro33-mediated in-
creased adhesion was observed in two independent sets of cell
lines (Table 1), demonstrating that clonal variation cannot
account for the di¡erent phenotype observed. Cadroy et al.
[24] assessed the relationship of shear and Pro33 for platelet
adhesion on tissue factor and collagen, and found that com-
pared to the Pro33-positive platelets, more Pro33-negative
platelet deposited on tissue factor, but not collagen at
650 s31. The apparent di¡erences between our studies may
be due to the fact that neither of these substrates are ligands
for KIIbL3 and/or the di¡erent shear forces used. The Pro33-
dependent enhanced adhesion in our study was observed with
the other major KIIbL3 substrate, vWF, both in its puri¢ed
form and in cryoprecipitate. Comparing the relative e¡ects
across the various substrates suggests that the Pro33 e¡ect
under shear is greatest on ¢brinogen and that cryoprecipitate
favors more cell adhesion, perhaps due to cooperativity be-
tween the multiple KIIbL3 ligands.
In this study we used a range of wall shear rates typically
chosen to study adhesive interactions between a suspension of
£owing leukocytes (cells of size similar to CHO) and cultured
endothelial cells [25]. We found that rather low shear rates
were required to observe the Pro33-dependent e¡ect on adhe-
sion, since little or no cell adhesion was observed at £ow rates
above 125 s31. It is di⁄cult to directly correlate shear forces
in the parallel-plate £ow chamber with arterial or venous
shear because the heterologous cells used in this study express
only integrin KIIbL3 and lack the GPIb^IX complex that slows
platelets in vivo. This is analogous to the situation in which
human platelets lacking GPIb^IX adhere to collagen sub-
strates at venous but not arterial shear forces [26]. Further-
more, the large size of the CHO cells compared to smaller
platelets substantially increase the drag force applied to the
KIIbL3^ligand bond. Despite these inherent limitations in our
model system, the key ¢nding from our studies is that shear
force augments the Pro33-dependent increase in cell adhesion.
It is not clear how shear would selectively confer enhanced
adhesiveness to Pro33 cells. Immuno£uorescence studies in
Fig. 3 indicate that a di¡erence in integrin KIIbL3 clustering
does not explain the enhanced Pro33 cell binding to ¢brinogen
under shear. The increased relative £uid velocities during £ow
could increase the rate of KIIbL3^¢brinogen bond formation
(kinetic e¡ect) in Pro33 cells, as demonstrated for L-selectin-
mediated rolling [27]. Alternatively, shear forces could cause a
high-a⁄nity conformation for the receptor KIIbL3 in Pro33
cells as shown for KvL3 [6] and decrease the bond o¡-rate.
Our experiments suggest that the bond o¡-rate may not be
in£uenced by the Leu33Pro polymorphism, since both the
Leu33 and Pro33 cells that adhered on ¢brinogen at 25 s31
could not be dislodged even after increasing the shear rate up
to 1000 s31 at the end of the perfusion (data not shown).
Studies using surface plasmon resonance spectroscopy suggest
that KIIbL3^¢brinogen binding consists of two consecutive
processes: an initial fast reaction, with a reversible low a⁄nity
complex and a subsequent slower high a⁄nity complex [28]. It
is plausible that the combined presence of shear and the L3-
helix disrupting residue proline could change the kinetic rates
(and increase the on-rate) of integrin KIIbL3 to ¢brinogen at
one or both these steps.
Previous studies have demonstrated that integrin-dependent
adhesion is regulated by post-receptor signaling through the
COX pathway, both in £owing leukocytes [29] and static en-
dothelial cells [30]. Our study indicates that under shear the
KIIbL3 Pro33-mediated enhanced adhesion also depends on
COX (Table 2). We have observed a similar dependence under
static studies (data not shown). Our studies led to an interest-
ing and unexpected ¢nding: aspirin enhanced the adhesion of
Leu33 cells. This e¡ect was observed primarily under low
shear stress (25 s31) and not higher shear stresses (50 or
100 s31) and under the higher ¢brinogen concentrations (50
Wg/ml and 100 Wg/ml) and not the lower ¢brinogen concentra-
tion (12.5). Note that aspirin only inhibited and never en-
hanced Pro33 cell adhesion under any condition. This e¡ect
of aspirin on Leu33 cells was very reproducible. Furthermore,
this data is consistent with a study demonstrating an increased
platelet aggregation with a higher plasma ¢brinogen concen-
tration only in Pro33-negative but not Pro33-positive subjects
[17].
What is the functional signi¢cance for a shear-enhanced
adhesiveness of the Pro33 cells? Pro33 platelets have been
reported to be prothrombotic in some but not all clinical
Table 2b
Relationship of shear rate and aspirin on CHO cell adhesion
Shear Ethanol ASA (300 Wg/ml)
LK Leu33 Pro33 LK Leu33 Pro33
25 s31 0.43U .18 20.56U1.76 53.81U 3.39, P6 0.001* 0.5U .18 30.31U 1.18, P6 0.0012 33.4U 1.81, P=0.068*
50 s31 0.31U .17 21.06U1.30 35.18U 1.40, P6 0.001* 0.25U .11 23U .98, P=0.292 16.8U 1.46, P=0.046*
125 s31 0 8.63U .79 13.6U 1.01, P=0.006* 0.1U .09 8.7U 1.07, Ps 0.052 10.09U .62, P=0.175*
Numbers in table are number of cells per microscopic ¢eld adhering to 100 Wg/ml ¢brinogen. *P values for Leu33 vs. Pro33. 2P values for
Leu33 ethanol vs. Leu33 aspirin.
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epidemiology studies [11] and in this in vitro study we show
shear forces amplify by two- to four-fold the Pro33-mediated
enhanced adhesion to ¢brinogen. Perhaps some part of the
inconsistency in clinical studies stems from variability in arte-
rial shear forces among the heterogeneous vascular lesions
among di¡erent patients. Our ¢ndings that shear force enhan-
ces the adhesive phenotype of Pro33 cells are consistent with
the fact that many clinical epidemiology studies have found an
association between the Pro33 polymorphism and arterial
thrombosis, but none have found an association with venous
thrombosis [31^34]. According to our presented data the big-
gest risk of the Pro33 polymorphism would be at moderate
shear stress likely to be seen in atherosclerotic intermediate
sized vessels. Hence a possible consequence of the Pro33 poly-
morphism could be to increase the platelet recruitment and
the speed of growth of a thrombotic lesion. Aspirin has been
reported to be of some bene¢t in the prevention of venous
thromboembolic disease [35]. Since our study shows enhanced
adhesion of Leu33 cells under low shear/high ¢brinogen con-
ditions, it would be very interesting to assess whether plasma
¢brinogen levels and the Leu33Pro polymorphism interact to
modulate the e¡ects of aspirin on the prevention or develop-
ment of venous thrombosis. In conclusion, the Leu33Pro
polymorphism is shown to regulate the adhesive behavior of
cells to the ECM proteins in a substrate-speci¢c manner, and
£uid shear stress can further enhance the adhesive phenotype
of Pro33 cells. Future clinical pharmacogenetic studies will be
required to consider whether Pro33-positive patients may de-
rive more prothrombotic bene¢t from cryoprecipitate infu-
sions and more antithrombotic bene¢t from aspirin compared
to Pro33-negative patients.
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